Novo Nordisk is ending its relationship with the company, removing its ability to sell the uber-popular drug Wegovy. Novo alleges Hims & Hers was not following standards and was endangering patient ...

EPA-EFE/Ida Marie Odgaard DENMARK OUT July 9 (UPI) --The Hims & Hers wellness platform announced Wednesday it will soon offer a generic version of the weight loss drug semaglutide in Canada as Novo ...

Novo Nordisk stock collapsed 26% in its worst trading day ever after slashing guidance on Wegovy sales and naming a new CEO.

Novo Nordisk ended a short-lived agreement to sell its Wegovy weight-loss drug through Hims & Hers Health on Monday, sending shares of the U.S. telehealth company plunging more than 30%.

San Francisco telehealth company Hims & Hers saw its stock plunge more than 30% earlier this week after a partnership with ...

Telehealth company Hims & Hers is facing a growing number of U.S. investor lawsuits after Novo Nordisk's decision last month to end a short-lived partnership to sell its Wegovy weight-loss drug ...

On April 29, 2025, Hims & Hers and Novo Nordisk unveiled a landmark collaboration to bring Wegovy—Novo's blockbuster ...

U.S. equities were higher at midday as concerns oil prices would spike because of the U.S. attack on Iran diminished.

Novo Nordisk announced it is cutting ties with telehealth giant Hims & Hers Health, pulling its blockbuster drug Wegovy from ...

Starting at $599 per month, some people were able to get prescribed to Wegovy and a Hims & Hers membership. That was much cheaper than the previous cost of paying $1,999 per month for Wegovy on ...

The healthcare company Hims & Hers Health offers compounded doses of semaglutide, the drug behind Wegovy, that adjust dose levels to help patients manage side effects.

In May 2024, Hims & Hers began offering access to GLP-1s, first in the form of compounded injectable semaglutide, and in August 2024 in the form of branded (or FDA approved) injectable semaglutide.